On October 11, 2019, the U.S. Food and Drug Administration (FDA) approved the Secuado transdermal system, the first transdermal patch formulation for the treatment of adults with schizophrenia. The Secuado transdermal system contains asenapine, an atypical antipsychotic. Noven Pharmaceuticals plans to launch Secuado in early 2020. The Secuado transdermal system is an adhesive patch that is applied to the skin once daily. The transdermal drug delivery system (TDDS) provides sustained concentrations during a 24-hour wear time. Secuado should be applied to clean, dry, and intact skin on the upper arm, upper back, abdomen, or hip. The transdermal system . . .